In the Claims

Please amend claims 91, 92, 97 and 105. This listing of the claims will replace all prior versions, and listings, of claims in the application.

LISTING OF THE CLAIMS

1. (previously presented) A method of enhancing migration of calcium-sensing receptor expressing cells to a specific site in a subject, comprising:

locally administering to a specific site in a subject in need of such treatment a nonCa^{++} calcium sensing receptor agonist in an amount effective to enhance migration of calcium-sensing receptor expressing cells to the specific site in the subject.

2-9. (Cancelled)

10. (previously presented) A method of inhibiting migration of calcium-sensing receptor expressing cells to a specific site in a subject, comprising:

locally administering to a specific site in a subject in need of such treatment a calcium-sensing receptor antagonist in an amount effective to inhibit migration of calcium-sensing receptor expressing cells to the specific site in the subject.

11-84. (Cancelled)

85. (previously presented) The method of claim 1, wherein the calcium-sensing receptor expressing cells are hematopoietic cells.

86. (amended) The method of claim ~~2~~ 85, wherein the hematopoietic cells are hematopoietic progenitor cells.

87. (previously presented) The method of claim 1, wherein the calcium-sensing receptor expressing cells are neural cells.

88. (previously presented) The method of claim 1, wherein the calcium-sensing receptor expressing cells are epithelial cells.

89. (previously presented) The method of claim 1, wherein the calcium-sensing receptor expressing cells are mesenchymal cells.

90. (previously presented) The method of claim 1, wherein the calcium-sensing receptor expressing cells are endothelial cells.

91. (amended) The method of claim 1, wherein the nonCa^{++} calcium-sensing receptor agonist is ~~NPS R-467~~ R-N-(3-methoxy-α-phenylethyl)-3-(2'-chlorophenyl)-1-propyl amine (NPS R-467) or salts thereof.

92. (amended) The method of claim 1, wherein the nonCa^{++} calcium-sensing receptor agonist is ~~NPS S-467~~ (S)-N-(3-methoxy-α-phenylethyl)-3-(2'-chlorophenyl)-1-propyl amine (NPS s-467) or salts thereof.

93. (previously presented) The method of claim 10, wherein the specific site is a site of inflammation.

94. (previously presented) The method of claim 93, further comprising co-administering a non-calcium-sensing receptor antagonist that inhibits migration of immune cells to the site of inflammation in the subject.

95. (previously presented) The method of claim 94, wherein the non-calcium-sensing receptor antagonist is an antiinflammatory agent.

96. (previously presented) The method of claim 10, wherein the subject has an autoimmune disease.

97. (amended) The method of claim 96, wherein the autoimmune disease is rheumatoid arthritis, uveitis, insulin-dependent diabetes mellitus, hemolytic anemias, rheumatic fever, Crohn's disease, Guillain-~~Bane~~ Barre syndrome, psoriasis, thyroiditis, Graves' disease, myasthenia gravis, glomerulonephritis, autoimmune hepatis, or systemic lupus erythematosus.

98. (previously presented) The method of claim 10, wherein the subject has an abscess, a transplant, an implant, atherosclerosis, or myocarditis.

99. (previously presented) The method of claim 10, wherein the calcium-sensing receptor expressing cells are hematopoietic cells.

100. (previously presented) The method of claim 99, wherein the hematopoietic cells are hematopoietic progenitor cells.

101. (previously presented) The method of claim 10, wherein the calcium-sensing receptor expressing cells are neural cells.

102. (previously presented) The method of claim 10, wherein the calcium-sensing receptor expressing cells are epithelial cells.

103. (previously presented) The method of claim 10, wherein the calcium-sensing receptor expressing cells are mesenchymal cells.

104. (previously presented) The method of claim 10, wherein the calcium-sensing receptor expressing cells arre endothelial cells.

105. (amended) The method according to any of claims 10 or 93-104, wherein the calcium-sensing receptor antagonist is ~~NPS-2143~~ N-[(R)-2-hydroxy-3-(2-cyano-3-chlorophenoxy) propyl]-1-dimethyl-2-(2-napthyl) ethylamine (NPS 2143).